PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

a soluble guanylate cyclase activator and an off-the-shelf, virus-specific T cell therapy. These advances herald new hope for people with kidney disease. New data demonstrate that in people with ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. Three ...

inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability across the spectrum of pulmonary ...

a soluble guanylate cyclase activator and an off-the-shelf, virus-specific T cell therapy. These advances herald new hope for people with kidney disease.

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

Linaclotide Plecanatide Guanylate cyclase C receptor agonist. Increase of intra and extra-cellular cyclic guanosine monophosphate. Dose-dependent diarrhea. Increase of secretion of chloride ...